Recent Advances and Strategies for the Management of CIN and HPV Eradication Starategies for the Prevention of Uterine Cervical Cancer

Dear Colleagues,

Managing cervical intraepithelial neoplasia (CIN) involves both treatment and follow-up, with HPV eradication strategies focused on preventing future infections through vaccination and early detection by regular screening. Every year, approximately 600,000 women worldwide are diagnosed with cervical cancer, and an estimated 340,000 women died from the disease in 2020. In Japan, however, the number of cervical cancer cases among women aged 20 to 39 is on the rise, alongside an increasing mortality rate. We invite you to submit research to this Special Issue titled “Recent Advances and Strategies for the Management of CIN and HPV Eradication Starategies for the Prevention of Uterine Cervical Cancer”, exploring the central theme of preventing uterine cervical cancer, divided into primary and secondary prevention. Primary prevention focuses on the use of HPV vaccines, while secondary prevention involves the diagnosis and management of CIN. We invite manuscripts related to vaccine trials (both preclinical and clinical) and strategies for developing more effective HPV vaccines. Our objective is to compile a range of research addressing the various aspects of HPV that could contribute to more effective strategies for eradicating HPV infection. Potential research areas include, but are not limited to, the following:

• Diagnosis of CIN;
• Gynecologic and obstetric risks;
• Therapeutic effects of treatment.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Cancers.

Dr. Masaru Sakamoto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.